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Abbreviations 
NICE National Institute of Clinical Excellence 
AAGBI Association of Anaesthetists of Great Britain and Ireland 
CV coefficient of variation 
CI Confidence interval 
T1, T2, T3 and Tp First, second, third and peak tryptase samples 
UMH Urinary Methylhistamine 
WAO World Allergy Organisation 
IQR interquartile range 
'7p20% positive change in tryptase >= 20% from trough to peak 
'7p3 positive change in tryptase level from trough to peak of >=3 Pg/L 
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Abstract 
Background 
Sheffield NARCOS (National Adverse Reactions Advisory Service) investigates suspected 
perioperative anaesthetic reactions using serial tryptase, urinary methylhistamine and 
clinical information. Further recommendations for additional allergy clinic assessment are 
provided. 
Objective 
To establish a robustly measurable protocol for identifying mast cell mediator (MMR) release 
in this cohort. To compare these thresholds with previous suggested thresholds and 
algorithms.  
Method 
A review of 3,455 NARCOS cases referred with a suspected peri-operative allergic reaction. 
Tryptase, Urinary methylhistamine (UMH) and clinical details were analysed. 1746 cases 
were graded using the Ring and Messmer scale. Reaction grade, tryptase and UMH 
changes were compared with statistical and graphical presentations appropriate to non-
normally distributed measurements using Analyse-IT software. 
Results 
Sensitive strategies such as 3Pg/l or 20% are measurable, translatable and would 
substantially increase detection of potentially relevant changes in tryptases. Adequate 
quality assurance for low level measurement is needed.  
 An incremental threshold of 20% would identify potential MMR in an additional 14% of 
cases with peak tryptase (Tp) between 5 and 14Pg/L and a further 15% with Tp below 
5Pg/L. Further work is required to establish the diagnostic performance characteristics of 
this more sensitive approach. 
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UMH also identified up to 120 further cases of potential MMR in absence of tryptase 
increments. 
Conclusion and Clinical Relevance 
Future studies should establish and compare the predictive performance characteristics of 
each strategy against clinical phenotypes. A single agreed definition of positive serial 
tryptases is needed to enable robust evaluation of diagnostic strategies. This could serve as 
a harmonised standard for comparative studies of case series from different centres. 
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Introduction: 
The optimum number of tryptase measurements and the best interpretative strategy have 
not yet been established in peri-operative anaphylaxis. The predominant diagnostic indicator 
in allergy diagnosis is the clinical history and most tests are thought to be less reliable. 
However the tests, and their interpretation, are the most amenable to standardization or 
harmonization. There have been few large reviews of investigation of perioperative 
anaphylaxis and the optimal diagnostic test combination remains unknown. The reference 
diagnosis in those studies is predominantly based on clinical criteria derived from expert 
opinion and observational studies (WAO International Consensus 201 [1], National Institute 
of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network [2] and AAGBI 
Guidelines 2009 [3].  However neither clinical criteria, nor a single robust standardised 
tryptase interpretation protocol have been subjected to extensive clinical evaluation, and it is 
very difficult to remove mimics of anaphylaxis from the studies. Allergen triggers are only 
identified in half of the cases in many series [4] [5] [6] [7] [8] [9] [10]. We do not know if 
current presumptions of poor sensitivity of tryptase testing are biased by lack of specificity of 
the clinical criteria or insensitivity of the tests interpretive criteria. 
This causes a particular problem when deriving performance characteristics for diagnostic 
tests in anaesthetic allergy, since a diagnostic drug challenge is often impractical. There are 
many mimics of the clinical picture of anaphylaxis, including direct mast cell mediator 
release and other causes of hypotension and bronchospasm, including the pharmacological 
action of the drugs themselves. Harmonisation of diagnostic test performance measurement 
is possible and can serve as a fixed point of reference to enable derivation of translatable 
performance characteristics.  In addition the optimum number of tryptase samples has not 
been validated, although recently various sampling criteria have been proposed based on 
clinical opinion and knowledge of tryptase half-life data [11] [12] [13] [14] [15]. 
We examined the last 3,455 cases in NARCOS, a national service for the laboratory 
investigation of adverse anaesthetic drug reactions based in Sheffield, England, to evaluate 
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the performance of serial tryptase and urinary methyl histamine measurement. We 
compared the results against published criteria for clinical grading of reactions. 
 
Methods 
Data 
We conducted a retrospective survey of the NARCOS database containing the laboratory 
and clinical information on all samples referred to Sheffield for NARCOS assessment, 
including tryptase (T) blood tests or urinary methyl histamine (UMH) tests taken at the time 
of reaction and 24 hours later.  Our required proforma protocol advised serial tryptase 
measurements immediately, 1-6 hours after reaction and at 24 hours.  Most patients had at 
least 2 serial tryptases (3400), but there was likely to be a wide variation in actual timing, 
with potential inaccuracies introduced in some during sample labelling, laboratory sample 
handing and referral onwards. Samples were therefore analysed according to their labelled 
temporal sequence as T1, T2 or T3. 
Analysis 
All statistical and graphical analysis was performed using Analyse-IT software V4.0 
(Analyse-IT software ltd, Leeds, UK).  3HDUVRQ¶s, SSHDUPDQ¶VDQG.HQGDO¶V7DXZHUHXVHG
for analysis of correlation of Tryptase with grade; Wilcoxon Median Differences for 
differences in the medians. Median and 95% confidence intervals are plotted because the 
data is not normally distributed. Analyte measurements, incremental changes and 
distributions were compared with reaction grade and the number of patients in each cohort 
who exceeded each threshold incremental changes from peak to trough were tabulated as 
detailed below. Performance of the threshold incremental strategies in those patients with 
peak tryptase above and below the ³reference range´ for both 11.4 (95th centile) and 14Pg/L 
(99th centile) cut-off levels were compared. 
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Quality Control 
Local tryptase assay validation data (ImmunoCAP, Sweden Diagnostics) demonstrated a 
coefficient of variation (CV) of 10% or less across the measurable range to 3.5Pg/L 
(CV=5%). Therefore a change of tryptase value >=20% can be determined to be the 95% 
confidence interval for a real and measurable change in this assay; this was the minimum 
value used to determine a true change in tryptase between samples. For values of less than 
3Pg/L a very rigorous threshold of a 100% increase was used (a 2-fold change) for 
comparison, to avoid over-interpretation of changes at low levels. The 3Pg/L threshold has a 
very similar effect to the (1.2xbaseline plus 2Pg/L) threshold used in some studies. The 
upper limit of normal of 14Pg/ml was validated locally as our 99th centile reference range 
FRQVLVWHQWZLWKWKHPDQXIDFWXUHU¶s data which quotes the 95th centile as 11.4Pg/L). Utilising 
a simple incremental threshold of 3Pg/L conveniently represents a 300% increase at 1Pg/L, 
a 100% increase at 3Pg/L, a 60% increment at 5Pg/L, a 26% increment at 11.4 and a 21% 
increment at 14Pg/L. It also has the benefit of simplicity.  
Throughout the study a single tryptase method (UniCAP, Thermo Scientific, Uppsala, Sweden) 
and single UMH assay (Pharmacia, Uppsala, Sweden) was used. Tryptase assays performed 
well in Internal quality control and external quality assurance (UK NEQAS Tryptase) and the 
between laboratory CV for all available analyser groups in the scheme are comparable and 
under 10% worldwide. 
The urinary methyl histamine assay was validated in house and has a CV of <20% with a locally 
verified reference range cut-off.                                                                                                                                  
Creatinine-corrected values were reported and positive results defined as greater than 25 Pg 
/mmol creatinine (the 95th centile of normal urines locally validated). Creatinine assays were 
subjected to satisfactory UK NEQAS assessment throughout, but no EQA currently exists for 
UMH. 
The confounding variable of sample mislabeling in sequence or timing, or variability in 
individual tryptase kinetics is compensated for by utilising peak to trough changes ('7p.  
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Results 
Case mix and sampling 
3455 cases were referred between January 1998 and May 2015 (1271 males and 2184 
females). Twice as many females were referred. 12 cases were excluded because the 
laboratory failed to send the accompanying samples. 43 cases had single tryptase 
measurement and were excluded; of which 33% were >=14Pg/L and 40% >=11.4Pg/L. 
Only 7 / 3455 (0.2 %) of the procedures were reported to have been abandoned. 41/ 3455 
(1.2 %) deaths were noted (many post-operative), but definitive outcomes are not yet known 
for the whole cohort. 
Tryptase Sampling and levels 
3400 cases had 2 or more tryptase samples (98%); 71 % (2410) had a 3 tryptase series. 
29% (990) had only two tryptases performed.  
The first tryptase was raised in most cases, but the median peak values are relatively low, 
with only 232 being >100 and 88/232 > 200Pg/L (2%).  
1395/3400 (41% of the referred samples) had had a peak tryptase (Tp) >=14Pg/L and 45.6% 
were >11.4Pg/L on any one of the three samples (Table 1 & 2). The first raised tryptase was 
usually the first sample (T1): 1312 had a raised T1; 92 had a normal T1 but raised second 
sample (T2) and 8 (0.5%) had a normal T1 and T2 but a raised T3.  Tryptase results are not 
normally distributed in any reaction class. Median peak (highest) tryptase in the positive 
cohort was 39.5Pg/L (IQR 22.6-39.5). Median tryptase in all raised T1 samples was 
35.5Pg/L. Ratios of trough to peak tryptase ranged from 0 to 8400% increase. 
Increments fail to identify the 21 (0.6%) cases where tryptase is >200Pg/L (above the 
measuring range of the assay) throughout T1, T2 and T3 samples (i.e. not exceeding a 
3Pg/L or 20% change), and those where the tryptase drops less than 20% in the series. 
(Table 1-3). 20% changes were less sensitive than 3Pg/L in raised peak tryptases. Initial 
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single tryptase measurements can be misleading, as a few are initially very low (<5) and 
give no clues to the subsequent rise. 
Reaction Severity 
2053 (60%) of referrals provided clinical information: 1746 referrals had sufficient clinical 
information to grade the reaction according to the Ring and Messmer scale a further 307 
specified anaphylaxis, but without sufficient details to confidently grade. 
230 (13%) of 1746 requests were grade 1 reactions: 259 (15%) were grade 2; 33% (575) 
were grade 3; 37% (641) were grade 4 reactions, of whom 217 (12%) presented solely with 
hypotension. 41 fatal Grade 5 cases (2.4%) were declared (Figure 1).  
A single known mastocytosis case was identified at referral, with a clear additional acute 
change in tryptase levels.  
In the absence of any change in referral patterns we can therefore assume that >70% of the 
entire cohort of referrals would be grade 3-5 reactions. By definition all those cases grading 
at 3 and above on the ring and Messmer scale will have sufficient features to suggest likely 
anaphylaxis on the NAIA/FAAN definitions [2]. 
Tryptase in different reaction grades 
Median Tryptases and incremental tryptase levels rose with grade to grade 4 (Figure 1), but 
there was a wide range of peak tryptases with all grades, as previously documented. There 
was limited correlation between Tp and severity overall (Figure 1). The same was true of the 
UMH values (Figure 2). Significant differences between the median peak tryptase elevations 
(p<0.0001) between grade 1 all other reaction grades (2-5), with the exception of grade 2 to 
3 (p= 0.21) 3 to 4 (p= 0.62) and 4 to 5 (p=0.76). 
The 20% increment was most sensitive overall for detecting potential MMR, but interestingly 
was less sensitive in those with raised peak tryptases for either 95th or 99th centile reference 
ranges. 3Pg increments were less sensitive in all combinations (Tables 1-3). Few changes in 
low level Tp below 5Pg/L were above 100% although 20% changes were common (Tables 
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3a and 3b). Significant differences between the median peak to trough tryptase changes 
(p<0.0001) between grade 1 all other reaction grades (2-5), with the exception of grade 2 to 
3 (p= 0.21) 3 to 4 (p= 0.62) and 4 to 5 (p=0.76). Thus both peak tryptase and tryptase 
changes behave similarly. 
UMH in different reaction grades 
Urinary Methyl histamine was positive in 45-68% of patients and in most patients with 
positive tryptases. It is more frequently positive in higher grade reactions (Figure 2 and 
Table 4) but overall correlation was limited. 
UMH independently identifies patients with possible mediator release when there was no 
evidence of tryptase release, even on the most sensitive 20% criterion. 
593 cases (25% of the cohort with multiple tryptases) had UMH measurements.  414 were 
positive for UMH (mostly UMH1). 213 UMH measurements were available for cases where 
the reaction was graded (Table 4 and Figure 2) 
There were no strong correlation between UMH1 and T1 levels overall or in any subgroup 
(Correlation r all < 0.3) unlike that reported for plasma histamine. The majority of cases had 
simultaneous evidence of UMH and Tryptase release consistent with previous reports.  
UMH is raised without detectable tryptase in 3% of cases. 
100-120 cases (3% of the total cohort) were identified where UMH was raised without any 
detectable incremental change in tryptase (102 for 3Pg/L incremental threshold, 100 for a 
20% increment in tryptase and 120 for a 5Pg/L threshold). 
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Discussion 
Harmonisation of Tryptase interpretation is needed 
Establishing a diagnosis of drug allergy is still an imprecise activity. There is currently no 
evidence based consensus on criteria for establishing the presence of mast cell mediator 
release (MMR).  Clinical assessment has primacy, but in perioperative anaphylaxis there are 
many causes of hypotension and mimics of anaphylaxis, thus simply matching the WAO 
phenotype of anaphylaxis is of uncertain predictive value.  Elevated tryptase is reported in 
30-60% of reported series of anaphylaxis, but this may not translate to perioperative drug 
allergy or intravenous exposure. Guidelines exist to harmonise the evaluation of reactions 
(AAGBI, BSACI, NICE) [1] [16] [3] [17] [2] [18]. More evidence is needed for the performance 
characteristics of the available assays (tryptase and urinary methyl histamine) in large 
cohorts. Recent UK data suggests compliance with sampling recommendations can be poor 
[19] [20]. 
Tryptase presents a unique opportunity to harmonise diagnostic interpretation.  There is 
currently a single assay in routine use worldwide currently (although there have been 
several methods in the literature) [9] [21] [6]. Therefore de-facto standardisation of 
measurement is in place. 
What is the smallest incremental change that can be reliably measured? 
Rises as small as 20% or 2Pg/L or ROC thresholds of 5-7Pg/L have been observed to 
correlate with anaphylactic reactions in various studies [22, 23].  A compound index 
(1.2xbaseline + 2Pg/L) has also been proposed [13] [14].  
No one can reliably measure a change less than twice the routine coefficient of variation 
(CV) of the assay. Nor can anyone usefully translate a change of less than 2xCV this into 
clinical practice worldwide. Previous studies deriving ROC curves for Tryptase in small 
cohorts may not be translatable to other centres [15], however incremental changes may be 
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more translatable if validated on large series. Furthermore, clinical anaphylaxis is reported in 
WKH³DEVHQFH´RIPDVWFHOOPHGLDWRUUHOHDVH 
Incremental changes [24] [23] [22] [25] [26] between 20% and >100% have been proposed 
to add sensitivity. Non-anaphylactic reactions show a mean 29% change from baseline, in 
contrast to185% in emergency room anaphylaxis [27], allergic urticaria (49.5%) and non-
steroidal drug reactions (38.2%) [28].   A 35% increment correlated well with VIT reactions 
[25] and a change of 2Pg/L for anaphylaxis is sufficient in other scenarios [23] [22].   
It is important that natural or incidental variations in tryptase baseline levels will not confound 
any strategy. There is very little evidence for circadian changes and the variation observed 
in published datasets is small. Mean changes of less than 20% have been observed in 
venom immunotherapy (VIT) [29], post-operative orthopaedic procedures [30], emergency 
room admissions and controls [31] [32]. While statistically significant, many variations are 
within the 2xCV limits of the total tryptase assay (20%) [32] [30].  Liver disease and alcohol 
consumption do not raise tryptase [33] but renal impairment [34] [35] [36], obesity [13], 
interference form heterophile antibodies [21] and chronic elevations of uncertain significance 
may (Egner personal observation). 
Correlation between severity and peak tryptase or incremental changes is limited 
No strong correlation was seen between peak tryptase and reaction grade overall 
3HDUVRQ¶V6SHDUPDQ¶VU &,-DQG.HQGDOO¶V7DXU &,-0.26). The 
correlation between reaction severity and tryptase is always limited similar to this cohort [37] 
[20] [14], implying that tryptase is insensitive or there are non-allergic mimics of all grades of 
reaction which confound the analysis of all studies.  Peak tryptases in all grades of reaction 
can be small and within the reference range [26].  We show a statistically significant 
difference in median peak tryptase (or tryptase increment) and grade 1 for all reaction 
grades, but not between grade 2 and 3, 3 and 4 or grade 1 and 2, possibly due to difficulties 
in differentiating these grades clinically. 
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How should Tryptase be used in establishing MMR? 
The clinical criteria for anaphylaxis define features that suggest anaphylaxis clinically but do 
not exclude mimics. To assist in establishing mast cell mediator release in perioperative 
allergy, we must define a standardized and robust (i.e. translatable) approach to defining 
changes in markers, since derivation of ROC thresholds in previous cohorts erroneously pre-
supposes definitive diagnosis of drug allergy against a validated reference standard. 
The role of tryptase measurement should be to reliably identify those patients with tryptase 
changes that could represent mast cell mediator release. This large case series suggests 
that small changes in tryptase are robustly measurable and potentially useful.  We establish 
that a threshold of 20% increment should be the minimum change that can be measured 
with certainty and that a simple increment of 3 Pg/L from peak to trough may be a more 
specific alterative and functions similarly to the (1.2xbaseline+2) algorithm within the 
reference range.  Both require large scale validation since they may identify potential 
tryptase release in 30-60% of patients with peak tryptases within the reference range. We 
show that a few additional cases of likely MMR (3%) can only be detected by UMH analysis. 
This may be a useful adjunct for lesser degrees of reaction which are less likely to produce 
large tryptase increments within the reference range. 
No test is without false positives or false negatives; the 3Pg/L strategy minimizes likely false 
positivity at lower levels in a similar way to previously suggested algorithms such as (1.2 x 
baseline) + 2Pg/L, but the possibility that a 20% rise may of significance at all levels of 
tryptase remains to be proven. Simple peak tryptase thresholds including T>=14Pg/L, 
>=11.4Pg/L or lower are insensitive, with anaphylaxis and IgE mediated drug reactions seen 
with peak tryptases much lower than 14Pg/L [26] [23] [24]. This series confirms that the half-
life of tryptase appears to be markedly prolonged in some cases [28]. Despite these caveats, 
the evaluation of small serial changes is both rational and justified.  
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A peak tryptase of >=14Pg/l is the ³correct´ threshold for identifying individuals with raised 
tryptase. 11.4Pg/l is too sensitive since RI³QRUPDO´SHRSOHZLOO always exceed this 
leading to erroneous suspicion of elevation in normal people (Tryptase Kit insert 
http://www.phadia.com/en-GB/5/Products/ImmunoCAP-Assays/ImmunoCAP-Tryptase/ and 
Sheffield local validation data). Utilising incremental changes largely negates this 
disadvantage and gives similar performance irrespective of the threshold used (Tables 1-3).  
Both strategies are independent of assumptions about accuracy of sample labelling timing or 
sequence. They make no assumptions about the kinetics of clearance. Laboratories wishing 
to interpret changes to the 3Pg/L threshold will need to establish extra IQC strategies for 
very low values that are not in place routinely.  
Increments are less useful in raised tryptases 
Utilising increments in tryptase will only miss those cases with slow clearance or 
inappropriately short intervals between samples.  Acute rises always fall, thus tryptase 
changes of greater than 3Pg/l can be expected in almost all of these raised samples (except 
21 case where tryptase remained >200Pg/l throughout (i.e. above the upper measuring limit 
of the assay). 20% increments (or the 1.2xBaseline+2 algorithm) fare slightly less well 
because the absolute size of a 20% increment at 100Pg/l is 20Pg/l and at 50 it is 10Pg/l.  
The role of Urinary Methyl Histamine 
We show that raised UMH can be seen in the absence of significantly raised tryptase [38] 
[13].  Further studies are needed to determine if UMH might identify additional cases of mast 
cell mediator release [39] [38]. In our cohort, 80% of patients with tryptase release had 
simultaneous UMH release. Conversely 3% had no evidence of tryptase increments (on any 
measure) but had positive UMH levels.  This additional information may be useful increment 
in diagnosis and risk assessment. 
Summary 
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This data provides the first clear indication of the expected levels of serum tryptase in a 
large cohort of suspected perioperative anaphylaxis, utilising the only routinely available 
assay for total tryptase.  UK NEQAS External quality assessment data suggest that the 
majority of participants have assay performance readily able to detect small increments 
reliably (UK NEQAS Tryptase scheme reports www.immqas.org.uk) meaning that the 
conclusions are readily translatable to other centres provided laboratories extend their 
internal controls to reliably report below 3Pg/L. 
Conflict of Interest: None 
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Figure legends: 
 
Figure 1: Larger Tryptase changes are seen in higher grades of reaction but overall correlation 
is poor  
 
Data includes 1746 graded reactions and 307 reactions labelled anaphylaxis (grade uncertain). 
Data is presented as Box and Whisker plots with medians (box shoulders = 95% Confidence intervals 
of median), quartiles (outer box represents 25th and 75th centiles) and max/min ranges. 
 
Peak tryptase  and peak to trough increment medians for reaction grades 3, 4& 5 were all statistically 
different from grade 1 dataset (Kruskall-Wallis p<0.0001). 
 
 
 
 
 
Figure 2: There is a trend to higher peak UMH with higher grades of reaction but overall 
correlation is poor. 
 
Anaphylaxis ungraded = referral stated ³DQDSK\OD[LV´EXWZLWKRXWVXIILFLHQWGHWDLOVIRUDFFXUDWHgrading. 
Data is presented as Box and Whisker plots) with medians (box shoulders = 95% Confidence 
intervals), quartiles (outer box represent 25th and 75th centiles and max/min ranges. 
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Table 1: Incremental changes are of most use within the reference range.  
 
A combination of raised tryptases and incremental changes within then reference range is best. 
20% changes are more common within the reference range than 3Pg/L increments within the 
reference range, but 5-10% of the raised tryptases do not change by these thresholds. 
 
'7p >20% = positive change in tryptase from trough to peak of >=20% 
'7p>3Pg/L = change in tryptase level from trough to peak of >=3Pg/L 
*21 (0.6%) additional cases where all tryptases were >=200Pg/L (without any measurable increment) 
could be identified. 117/1053 (11%) samples Tp<5Pg/L have '7p >=100% 
'7p>3Pg/L is rare below a peak tryptase of 5Pg/L, but changes of 20% are common although most 
are <100%.  43 of 1053 samples (4%) changed between 20 and 100% in low level samples below Tp 
=5Pg/L. 
  
 
'7p>3Pg/L 

'7p >20% 
 
 
All Tp (Peak Tryptase) 
(n=3400) 
 
 
1762 
(52%)* 
 
2750 
(81%) 
 
Tp<5 
(n=1053) 
 
14 
(1.4%) 
 
690 
(66%) 
 
 
4.9<Tp<14 
(n=952) 
 
418 
(44%) 
 
 
743 
(78%) 
 
Tp>=14 
n=1395 
 
 
1330* 
(95%) 
 
 
1316 
(94%) 
 
4.9<Tp<11.4 
(n=799) 
 
294 
(37%) 
 
664 
(83%) 
 
Tp>=11.4 
(n=1548) 
 
 
1452* 
(94%) 
 
1395 
(90%) 
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Table 2: Stratified combinations of thresholds may improve detection within the reference 
range 
 
Large changes in tryptase (>100%) below a peak tryptase of 5Pg/L are rare. 
Enforcing a requirement for a 100% change for tryptases below 5Pg/L reduces the sensitivity of a 
20% threshold but makes little difference to a 3Pg/L strategy.  
Further studies will be required to determine the clinical predictive values of each strategy in future 
studies using definitive structured clinical criteria to establish evidence of acute tryptase release 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 

'7p>3Pg/L 
 

'7p >20% 

 
All Tp levels 
n=3400 
 
1762 
(52%)* 
 
2750 
(81%) 
 
Tp>=14 +  
'7p between 5-14 +  
'7p>100%at <5 
 
 
1930 
(57%) 
 
2256 
(66%) 
 
Tp>=11.4 +  
'7p between 5-11.4 + 
'7p>100% at < 5 
 
 
1959 
(58%) 
 
2329 
(69%) 
[Type text] 
Table 3:   Incremental Tryptase changes within the reference range versus reaction grade have 
similar utility independent of the upper limit of the reference range used.  
 
Table 3a: Using 11.4 (95th Centile) as upper limit of reference range. 
 
 
 
 
 
 
 
Tp<11.4 
(n=946) 
 
 
 
Tp>11.4 
(n=800) 
n 
 
 
Reaction 
Grade 
 
 

'Tp>3Pg/L 
 

'Tp>20% 
 


'Tp>3Pg/L 
 

'Tp>20% 
 
307 
 
 
³$QDSK\OD[LV´ 
 
 
29/146 
(20%) 
 
 
68/146 
(47%) 
 
 
149/164 
(91%) 
118/164 
(72%) 
230 1 
 
32/179 
(18%) 
 
77/179 
(43%) 
 
 
47/51 
(92%) 
 
38/51 
(76%) 
 
259 2 
 
21/199 
(13%) 
 
91/199 
(46%) 
 
54/60 
(83%) 
52/60 
(87%) 
575 
 
3 
 
64/298 
(24%) 
131/298 
(44%) 
 270/277 
(98%) 
203/277 
(73%) 
641 
 
4 
 
37/249 
(15%) 
111/249 
(46%) 
 377/391 
(96%) 
281/391 
(72%) 
41 
 
5 
 
5/20 
(25%) 
10/20 
(50%) 
 20/21 
(95%) 
18/21 
(86%) 
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Table 3b: Using 14 (99th Centile) as upper limit of reference range. 
 
 
 
 
 
 
 
Tp<14 
(n=1014) 
 
 
  
 
 
Tp>14 
(n=732) 
 
n 
 
 
Reaction 
Grade 
 
 

'Tp>3Pg/L 
 
 

'Tp>20% 
 
 

'Tp>3Pg/L 
 
 

'Tp>20% 
 
307 
 
 
³$QDSK\OD[LV´ 
 
 
43/161 
(27%) 
 
 
 
78/146 
(48%) 
 
  
135/143 
(94%)  
118/143 
(72%) 
230 1 
 
43/192 
(22%) 
 
 
87/192 
(45%) 
   
36/38 
(96%) 
 
 
28/38 
(74%) 
259 2 
 
24/206 
(12%) 
 
 
102/206 
(50%) 
  
51/53 
(96%)  
47/53 
(89%) 
575 
 
3 
 
93/330 
(26%)  
133/330 
(40%) 
  236/245 
(98%)  
200/245 
(82%) 
641 
 
4 
 
51/265 
(19%)  
123/265 
(46%) 
  364/375 
(97%)  
269/375 
(72%) 
41 
 
5 
 
7/22 
(32%)  
13/22 
(59%) 
  18/19 
(95%)  
18/19 
(84%) 
 
 
20% Tryptase increments are more sensitive in the normal range, but less useful in raised tryptases 
than a 3Pg/L increment. 
100%. Changes in tryptase below 5Pg/L are rarely above 100% and are similar for all grades of 
reaction at 4% (19/543) 
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Table 4: Urinary methyl histamine identifies potential Mast cell mediator release in a further 3% 
(100) of cases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*UMH >25 Pg/mmol was found in 102 cases where '7p <3Pg/L and 120 cases where '7p <5Pg/L and 100 
cases. In all these cases no incremental tryptase changes are detected using the 3Pg/L or 20% 
incremental thresholds.  
 
  
 
Number of 
cases 
 
 
Reaction Grade 
 
UMH>=25Pg/mmol* 
(any sample) 
 
 
% UMH Positive 
 
18 
 
³DQDSK\OD[LV´ 
 
 
11 
 
61 
48 1 22 46 
 
45 
 
2 
 
19 
 
45 
 
86 
 
3 
 
56 
 
65 
 
151 
 
4 
 
102 
 
68 
 
7 
 
 
5 
 
 
3 
 
 
43 
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